Drug Trial Radar · NCT06071988
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Last checked: Nov 20, 2026Latest source record: Jan 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
558
Planned (sponsor's estimate)
Start
Nov 2, 2023
Primary completion
Sep 30, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Apurano Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates the long term efficacy and tolerability of the THC-focused nano endocannabinoid system modulator AP707 in patients with chronic pain disorders due to traumatic or post-operative peripheral neuropathy. Patients receive AP707 or placebo over the course of 14 weeks as an add-on to the standard of care. Changes in pain intensity, quality of life and sleep and others measures are monitored through different scales to assess the efficacy of AP707 in patients with chronic pain due to traumatic or post-operative peripheral neuropathy.
Conditions
- Pain
- Pain Syndrome
- Pain, Chronic
- Chronic Pain
- Chronic Pain Syndrome
- Neuropathic Pain
- Peripheral Neuropathy
- Peripheral Neuralgia
- Peripheral Nerve Injury
- Post Operative Pain
- Post-Traumatic Neuralgia
- Plexopathy
Interventions
Adezunap (AP707)Drug
Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
PlaceboDrug
Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)Time frame: Once daily in week 4 and 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie)
Munich, Bavaria, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.